Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on September 11, 2025
EIN Presswire Unveils First Case Study on Using Press Releases to Increase AI Search Visibility and Media Coverage
EIN Presswire
·
September 11, 2025
How My Home Pathway leveraged EIN Presswire to expand reach, enhance AI search visibility, and build media momentum. WASHINGTON , DC, UNITED STATES, September 11, 2025 /EINPresswire.com/ -- It’s no secret that people are increasingly using artificial …
Aesthetic Room Opens New Aesthetic Medicine Center in South Tyrol (Alto Adige) Near Merano and Bolzano
GlobeNewswire
·
September 11, 2025
Algund/Lagundo, South Tyrol (Alto Adige), Italy , Sept. 11, 2025 (GLOBE NEWSWIRE) -- Aesthetic Room, a new center for modern, minimally invasive aesthetic medicine, has officially opened in Algund, near Merano and Bolzano in South Tyrol / Alto Adige. The …
Global Brain Imaging Devices Market is Projected to Grow at a CAGR of ~6% by 2032 | DelveInsight
GlobeNewswire
·
September 11, 2025
New York, USA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Global Brain Imaging Devices Market is Projected to Grow at a CAGR of ~6% by 2032 | DelveInsight The brain imaging devices market is experiencing significant growth, fueled by the increasing incidence of …
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight
GlobeNewswire
·
September 11, 2025
New York, USA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight The bipolar disorder clinical trial landscape is evolving with 25+ therapies, namely, KarXT (BMS …
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
GlobeNewswire
·
September 11, 2025
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer A total of 105 HLA-A2 positive …
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites cellules
GlobeNewswire
·
September 11, 2025
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites cellules Un total de 105 patients HLA …
Mount Pleasant Group Becomes First in Canada to Offer Mushroom-Grown Coffins and Urns from Loop Biotech
GlobeNewswire
·
September 11, 2025
Toronto, Sept. 11, 2025 (GLOBE NEWSWIRE) -- In a Canadian first, Mount Pleasant Group (MPG) is proud to introduce the Loop Living Cocoon™ and Loop EarthRise™, revolutionary biodegradable funeral products grown from mushrooms. These nature-powered …
Faraday Pharmaceuticals to Participate in Upcoming Investor Events
GlobeNewswire
·
September 11, 2025
SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the …
RESTEM to Host R&D Day Highlighting its Next-Generation Immunomodulatory Treatment for Autoimmune and Inflammatory Diseases
GlobeNewswire
·
September 11, 2025
Leading KOLs to discuss the unmet needs and current treatment landscapes of idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), rheumatoid arthritis (RA), and facioscapulohumeral muscular dystrophy (FSHD) In-person and virtual R…
InnovAge Named as One of the Nation’s Best Workplaces in Aging Services™ by Fortune® and Great Place to Work®
GlobeNewswire
·
September 11, 2025
DENVER, Sept. 11, 2025 (GLOBE NEWSWIRE) -- InnovAge (NASDAQ: INNV), a leading provider of Program of All-Inclusive Care for the Elderly (PACE), has been named to the Fortune Best Workplaces in Aging Services ranking among the top 15 organizations in the …
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025
GlobeNewswire
·
September 11, 2025
Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …
Acentra Health CEO Todd Stottlemyer Named by Virginia Business to its ‘Virginia 500 Power List’ for Fourth Consecutive Year
GlobeNewswire
·
September 11, 2025
MCLEAN, Va., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, today …
Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance
GlobeNewswire
·
September 11, 2025
RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal …
MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
GlobeNewswire
·
September 11, 2025
CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy …
Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
GlobeNewswire
·
September 11, 2025
Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the …
Mass General Brigham’s Kraft Center Announces Winner and Finalists of the 2025 Kraft Prize for Excellence and Innovation in Community Health
GlobeNewswire
·
September 11, 2025
Boston, MA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inaugural $100k award goes to St. Louis company making a transformative impact in its community Organizations supporting maternal health and substance use disorder recognized as finalists Boston, MA – Today, …
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
GlobeNewswire
·
September 11, 2025
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage …
Rare Kidney Disease Community Members Join American Kidney Fund and IgA Nephropathy Foundation on Capitol Hill to Champion Key Legislation
GlobeNewswire
·
September 11, 2025
ROCKVILLE, Md., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation, joined by more than 50 advocates living with rare kidney diseases, are convening on Capitol Hill to rally support for policy …
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
GlobeNewswire
·
September 11, 2025
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persistent drug-related adverse events Results were leveraged to design confirmatory trial planned for 2026 FORT …
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
GlobeNewswire
·
September 11, 2025
ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its …